A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

The Johns Hopkins surgeon highlighted rapid growth at the agency, but pledged key staff will have “all the resources they ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.

Questioned by senators at a Thursday hearing, President Trump's FDA nominee said he would reevaluate which scientific topics ...

CBO Abbas Kazimi will replace longtime CEO Jeb Keiper as part of a planned leadership transition at the unorthodox drug ...

The struggling retail pharmacy chain entered an agreement to be purchased by private equity firm Sycamore Partners, which ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...